Roche launches two new antibodies to identify mutations in brain cancer

 

• Recent advances in cancer genomics have deepened the medical community’s understanding of the molecular alterations in brain tumours, more precisely subclassifying patients into specific diagnoses.
• Understanding a patient's brain tumour mutation status in the IDH1 and ATRX genes enables more informed clinical decisions and may improve patient outcomes.
• The IDH1 R132H and ATRX antibodies are the latest additions to Roche’s neuropathology portfolio, which contains 29 biomarkers.
  
  

 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer.

A brain tumour is formed when there is an abnormal growth of cells in the brain. There are two main types of cells in the brain: neurons, the communicators of the nervous system and glial cells, which support and protect neurons and maintain the body’s natural state of balance. Gliomas, brain tumours that develop from glial cells, are the most prevalent type of malignant brain tumours in adults.1

Gliomas that have mutations in the IDH1 and ATRX genes are biologically distinct from tumours that do not carry these mutations. Knowing a patient’s IDH1 and ATRX mutation status enables clinicians to provide personalised care to patients based on their specific tumour classification, including a more informed prognosis, the selection of targeted therapies and inclusion in clinical trials.2

https://www.globenewswire.com/news-release/2023/02/23/2613873/0/en/Roche-launches-two-new-antibodies-to-identify-key-clinical-mutations-in-patients-with-brain-cancer.html